Q1 EPS Estimate for Corcept Therapeutics Lifted by Analyst

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Equities researchers at Zacks Research boosted their Q1 2026 earnings per share estimates for Corcept Therapeutics in a research note issued to investors on Monday, January 27th. Zacks Research analyst K. Das now anticipates that the biotechnology company will post earnings per share of $0.46 for the quarter, up from their previous estimate of $0.45. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.35 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q2 2026 earnings at $0.56 EPS, Q3 2026 earnings at $0.74 EPS, Q4 2026 earnings at $0.74 EPS and FY2026 earnings at $2.50 EPS.

A number of other research analysts also recently issued reports on CORT. HC Wainwright reiterated a “buy” rating and issued a $80.00 price target on shares of Corcept Therapeutics in a report on Thursday, October 31st. StockNews.com downgraded shares of Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Monday, November 25th. Finally, Sandler O’Neill reissued a “buy” rating on shares of Corcept Therapeutics in a research report on Friday, October 18th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Corcept Therapeutics has a consensus rating of “Buy” and a consensus target price of $65.25.

Corcept Therapeutics Stock Performance

Shares of CORT stock opened at $60.66 on Wednesday. The firm has a market cap of $6.36 billion, a price-to-earnings ratio of 48.14 and a beta of 0.56. Corcept Therapeutics has a 52-week low of $20.84 and a 52-week high of $62.98. The company has a quick ratio of 3.64, a current ratio of 3.70 and a debt-to-equity ratio of 0.01. The company’s 50 day moving average is $55.45 and its 200 day moving average is $46.40.

Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $0.41 EPS for the quarter, beating the consensus estimate of $0.27 by $0.14. Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. The business had revenue of $182.55 million during the quarter, compared to analyst estimates of $171.97 million. During the same quarter in the previous year, the business posted $0.28 EPS. The company’s quarterly revenue was up 47.7% compared to the same quarter last year.

Insider Activity at Corcept Therapeutics

In other Corcept Therapeutics news, insider William Guyer sold 6,606 shares of the business’s stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $48.97, for a total transaction of $323,495.82. Following the sale, the insider now owns 5,796 shares of the company’s stock, valued at approximately $283,830.12. The trade was a 53.27 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Daniel N. Swisher, Jr. sold 2,200 shares of the firm’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $59.88, for a total transaction of $131,736.00. The disclosure for this sale can be found here. Insiders have sold 38,011 shares of company stock valued at $1,951,268 in the last ninety days. Corporate insiders own 20.50% of the company’s stock.

Institutional Trading of Corcept Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Hancock Whitney Corp raised its stake in shares of Corcept Therapeutics by 1.2% in the third quarter. Hancock Whitney Corp now owns 22,954 shares of the biotechnology company’s stock worth $1,062,000 after purchasing an additional 270 shares during the last quarter. KBC Group NV increased its holdings in Corcept Therapeutics by 21.3% in the 3rd quarter. KBC Group NV now owns 2,822 shares of the biotechnology company’s stock worth $131,000 after buying an additional 496 shares during the period. GAMMA Investing LLC raised its position in Corcept Therapeutics by 20.3% during the 4th quarter. GAMMA Investing LLC now owns 2,996 shares of the biotechnology company’s stock worth $151,000 after buying an additional 506 shares during the last quarter. Capital Performance Advisors LLP acquired a new stake in Corcept Therapeutics during the 3rd quarter valued at approximately $25,000. Finally, Bank of Montreal Can boosted its holdings in shares of Corcept Therapeutics by 5.0% in the 2nd quarter. Bank of Montreal Can now owns 12,156 shares of the biotechnology company’s stock valued at $395,000 after acquiring an additional 580 shares during the last quarter. Hedge funds and other institutional investors own 93.61% of the company’s stock.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.